Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh

(3:34)

Dr. Len Calabrese - EULAR 2018 Vasculitis Update on C5a Receptor Inhibitor in ANCA+ Vasculitis

(1:47)

C5a neutralization is protective in severe pneumonia

(3:51)

Researcher comment: The ADVOCATE trial | Peter Merkel

(8:9)

TAVNEOS® (avacopan) ASN Perspectives_Brant

(18:8)

KDIGO 2024 Guideline on ANCA-Associated Vasculitis: Update on Current Management and Treatment

(44:12)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

People with vasculitis talk about the one thing they wish people knew about vasculitis.

(6:11)

Partie 1 - Vascularites à ANCA : Point de vue du pneumologue

(23:12)

ANCA Associated Vasculitis

(45:24)

ANCA: The Vasculitis Antibodies

(16:59)

Prednisone: A Patient's Perspective

(9:33)

Dr Xavier PUECHAL Traitement des Vascularites à ANCA

(32:9)

ANCA Associated Vasculitis (Anti-Neutrophil Cytoplasmic Antibody) - Causes, Pathophysiology, Types

(10:34)

ANCA Vasculitis pathology

(27:28)

When Life Gives You Vasculitis-Dr Amal Thilakarathne \u0026 Spotlight on Rarity-SLE-Dr Madusha Jayasinghe

(1:1:47)

The Future of Steroid Use

(22:53)

Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis with Dr. Peter Merkel

(18:)

ChemoCentryx | Avacopan | Who is Drug Avacopan | Drug Tavneos | Uses Tavneos | Side Effect Avacopan

(1:52)

Avacopan

(1:23)

ANCA-Associated Vasculitis: plasma exchange, glucocorticoids and avacopan - PWR (Nov 2024)

(1:4:34)

Current issues in ANCA associated vasculitis

(1:21:45)

Current Treatments for GPA and MPA including Avacopan

(1:49)

FDA Approves Avacopan for Rare ANCA Autoimmune Disease

(1:47)

Clinical Trials in Vasculitis: What's New, What's for You

(34:24)

Vasculitis Abstracts from EULAR 2022

(2:30)

ANCA - Associated Vasculitis - EFIM YI Section

(1:6:43)

Advances in the Management of Complement-Mediated Kidney Diseases: A Year in Review

(17:45)

The ADVOCATE Trial: A Conversation with Dr. Peter A. Merkel

(19:59)

Enticing New Options in ANCA-Associated Vasculitis

(5:20)